We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

125 hedge funds and large institutions have $1.4B invested in Ventyx Biosciences in 2022 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 53 increasing their positions, 22 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,551% more call options, than puts

Call options by funds: $1.62M | Put options by funds: $98K

141% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 22

131% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 16

20% more funds holding

Funds holding: 104125 (+21)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

1% less capital invested

Capital invested by funds: $1.41B → $1.4B (-$12.9M)

4.47% less ownership

Funds ownership: 79.74%75.27% (-4.5%)

Holders
125
Holders Change
+21
Holders Change %
+20.19%
% of All Funds
2.01%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.1%
New
37
Increased
53
Reduced
22
Closed
16
Calls
$1.62M
Puts
$98K
Net Calls
+$1.52M
Net Calls Change
+$1.8M
Name Holding Trade Value Shares
Change
Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$124M +$8.77M +296,179 +9%
VP
2
venBio Partners
California
$114M -$45.9M -1,550,000 -31%
Capital International Investors
3
Capital International Investors
California
$69.3M +$62.6M +2,114,744 New
BlackRock
4
BlackRock
New York
$64.6M +$17.4M +588,360 +43%
Lord, Abbett & Co
5
Lord, Abbett & Co
New Jersey
$60.4M +$3.13M +105,629 +6%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$59.2M +$33.2M +1,120,232 +163%
Fidelity Investments
7
Fidelity Investments
Massachusetts
$55.6M -$5.96M -201,325 -11%
RI
8
RTW Investments
New York
$50.9M
Vanguard Group
9
Vanguard Group
Pennsylvania
$49.1M +$11.6M +392,218 +36%
Janus Henderson Group
10
Janus Henderson Group
United Kingdom
$48M -$34.5M -1,165,306 -44%
Adage Capital Partners
11
Adage Capital Partners
Massachusetts
$46.6M +$30.2M +1,021,245 +255%
VC
12
Vivo Capital
California
$42.7M -$1.56M -52,567 -4%
APM
13
Avidity Partners Management
Texas
$42.1M +$38.1M +1,285,000 New
PAMS
14
Pictet Asset Management (Switzerland)
Switzerland
$40.3M +$4.62M +155,989 +15%
CAM
15
Cormorant Asset Management
Massachusetts
$35.4M +$8.89M +299,997 +38%
DCM
16
Driehaus Capital Management
Illinois
$33.2M +$95.3K +3,217 +0.3%
TP
17
Third Point
New York
$32.8M -$98.1M -3,312,834 -77%
O
18
OrbiMed
New York
$30.3M +$20.7M +700,000 +311%
RG
19
Redmile Group
California
$29.3M -$13.9M -470,026 -34%
BC
20
Boxer Capital
California
$27.9M
TCM
21
TCG Crossover Management
California
$25.8M +$23.3M +787,231 New
QUSVM
22
Qiming U.S. Ventures Management
Washington
$24.5M
LGM
23
Logos Global Management
California
$21.5M -$21.9M -740,664 -53%
Wellington Management Group
24
Wellington Management Group
Massachusetts
$20M -$5.54M -187,172 -23%
State Street
25
State Street
Massachusetts
$18.1M +$3.29M +111,063 +25%

VTYX Hedge Fund Activity: Q4 2022 in Review

125 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q4 2022, worth a combined $1.4B — down 0.91% from $1.41B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new VTYX positions and 16 closed out — a net gain of 21 holders — while 53 added to existing stakes and 22 trimmed.

The largest buyer was Capital International Investors, opening a new position worth an estimated $62.6M. The largest seller was Third Point, cutting an estimated $98.1M.

  • 125 institutional investors held Ventyx Biosciences (VTYX) as of Q4 2022, up from 104 in Q3 2022.
  • Funds reported $1.4B of Ventyx Biosciences stock for Q4 2022, down 0.91% quarter-over-quarter.
  • 37 funds opened new Ventyx Biosciences positions in Q4 2022 and 16 closed out, a net change of +21 holders.
  • The largest Ventyx Biosciences buyer in Q4 2022 was Capital International Investors, an estimated $62.6M added.
  • The largest Ventyx Biosciences seller in Q4 2022 was Third Point, an estimated $98.1M sold.

Based on aggregated 13F filings for Q4 2022.